Body mass index and prevalence of obesity in a French cohort of patients with schizophrenia
Body mass index and prevalence of obesity in a French cohort of patients with schizophrenia
复制标题
DOI：
10.1111/j.1600-0447.2008.01208.x
复制
发表时间：
2008-07-01
影响因子：
6.7
通讯作者：
Rouillon, F.
中科院分区：
文献类型：
--
作者：
Limosin, F.;Gasquet, I.;Rouillon, F.
目标：为了解大样本精神分裂症患者的体重指数分布情况，探讨体重与抗精神病药物的关系，采用2005-2006年全国性调查的5756例精神分裂症患者的基线数据。患者的平均年龄为37.1 ± 11.8岁，平均BMI为25.5 ± 5.2 kg/m2。在最终的逻辑回归模型中，女性患者（年龄40-59岁vs. 18-29岁）、保护性就业患者（vs.无收入）、门诊患者（vs.全日制住院患者）和合并抗抑郁药治疗患者的肥胖患病率显著较高。有一个较高的肥胖率，相对于没有抗精神病药物在入口处，患者接受以下个别药物：氯氮平，奥氮平，利培酮和amisulprie.Conclusion：在非典型抗精神病药物治疗的患者，我们发现一个显着较高的肥胖患病率比那些没有治疗任何抗精神病药物。
Objective: To evaluate the distributions of body mass index in a large sample of patients with schizophrenia, and to examine the association between body weight and antipsychotic drugs.Method: The data source was baseline data from a national survey conducted in 2005-2006 in 5756 patients.Results: The mean age of the patients was 37.1 +/- 11.8 years, and the mean BMI was 25.5 +/- 5.2 kg/m(2). In the final logistic regression model, the prevalence of obesity was significantly higher in female patients, age 40-59 vs. 18-29 years, patients in sheltered employment (vs. no income), out-patients (vs. full-time in-patients) and patients treated with concomitant antidepressant. There was a higher rate of obesity, relative to an absence of antipsychotics at entry, for patients receiving the following individual drugs: clozapine, olanzapine, risperidone and amisulpride.Conclusion: In patients treated with atypical antipsychotics, we found a significantly higher prevalence of obesity than in those not treated with any antipsychotic medication.